Mendelian randomization analysis of genome-wide association data reveals that MRI-derived abdominal subcutaneous adipose tissue (ASAT) carries a 1.64-fold increased heart failure risk per standard-deviation increase (95% CI 1.40–1.93), while visceral adipose tissue showed only an imprecise positive trend and gluteofemoral fat showed no association. Critically, 67.9% of ASAT's heart failure effect was mediated through four cardiometabolic pathways—type 2 diabetes, systolic blood pressure, HDL cholesterol, and triglycerides—whereas BMI, despite similar risk magnitude (OR 1.65), showed only 8.5% mediation through those same pathways. The study drew on HERMES consortium outcome data from nearly 1.95 million individuals and 153,174 heart failure cases.
The finding challenges the prevailing clinical assumption that visceral fat is the primary imaging biomarker of cardiometabolic danger. ASAT has historically been considered metabolically 'passive,' yet this Mendelian randomization framework—which uses genetic instruments to approximate causal inference and reduce confounding—implicates it as a biologically coherent driver of metabolic syndrome-related heart failure. For clinicians, this suggests that routine waist circumference or BMI may substantially underestimate risk carried by subcutaneous abdominal depots visible only on MRI. Practical limitations are real: MRI-based fat phenotyping remains expensive and inaccessible at population scale, and the UK Biobank imaging cohort (38,965 participants) is predominantly European, limiting generalizability. Mendelian randomization also cannot fully exclude horizontal pleiotropy. This is a preprint not yet peer-reviewed, and mediation estimates carry wide confidence intervals warranting replication before clinical application. Still, the mechanistic clarity here is unusually compelling for an observational-genetics design.